新型非类固醇类固醇硫酶抑制剂含有谷氨酸单元的谷氨酸酸
Olga Ciupak1, Sebastian Demkowicz1, Janusz Rachon1
1Department of Organic Chemistry, Faculty of Chemistry, Gdansk University of Technology, Narutowicza 11/12, 80-233, Gdansk, Poland.
European journal of medicinal chemistry
|April 17, 2025
概括
新型类固醇硫酶 (STS) 抑制剂被合成和测试. 化合物54E在酶和细胞分析中显示出高活性,具有临床前开发的潜力.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 类固醇硫酶 (STS) 是类固醇代谢中的一个关键酶.
- 抑制STS对荷尔蒙依赖性疾病具有治疗潜力.
- 需要新的STS抑制剂来提高疗效和安全性.
研究的目的:
- 设计和合成基于库马林,胺,三醇和黄基架的新型STS抑制剂.
- 评估合成化合物的抑制活性和细胞效应.
- 研究最强大的抑制剂的分子相互作用和细胞吸收机制.
主要方法:
- 合成新型化合物,包括氨酸,氨酸,三醇,黄和谷氨酸部分.
- 分子建模以预测与STS活性部位的结合亲和力.
- 在体外酶分析测试以确定STS抑制.
- 使用JEG-3细胞进行细胞研究,以评估生物活性和IC50值.
- 通过有机阴离子载体多 (OATPs) 调查细胞吸收机制.
- 在斑马鱼幼虫中的体内毒性评估.
主要成果:
- 新型STS抑制剂已成功合成.
- 分子建模表明可能与STS活性部位结合.
- 化合物54E在酶和细胞测试中表现出最高的抑制活性.
- 化合物54E在JEG-3细胞中显示了22nM的IC50,与参考抑制剂Irosustat可比.
- 鉴定出OATP是54E细胞吸收的潜在媒介.
- 化合物54E在斑马鱼幼虫中没有显示出可检测的毒性.
结论:
- 化合物54E是一种强大且有前途的新型STS抑制剂.
- 采用特定支架和谷氨酸残留物的设计策略是有效的.
- 化合物54E的良好的细胞吸收和安全概况支持其进一步的临床前研究.
相关概念视频
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
114
Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...
114
Drug Metabolism: Phase II Reactions
3.4K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.4K
Phase II Reactions: Glucuronidation
150
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
150
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
97
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
97
Glucagon-like Receptor Agonists
261
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
261
Oral Hypoglycemic Agents: Sulfonylureas
154
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
154


